
Northrop Grumman topped Q4 expectations with adjusted EPS of $7.23 and GAAP EPS of $9.99 on $11.7 billion in sales (Q4 sales +10% YoY), while full-year sales reached $42.0 billion (+2% YoY) and GAAP net profit was $4.2 billion ($29.08/share). Free cash flow was $2.2 billion in the quarter and $3.3 billion for the year, leaving the company trading at ~24.4x P/E and ~30.5x P/FCF. Management guided to roughly 4% sales growth in 2026 to $43.8 billion, adjusted EPS of ~$27.65 and steady FCF of ~$3.3 billion, with a book-to-bill of 1.0 and backlog of $95.7 billion — guidance that implies slower growth and underpins the author's view that the stock is overvalued. Investors should weigh the earnings beat against weak forward guidance and rich valuation when positioning in defense equities.
Market structure: Northrop’s beat masks a structural pause — book-to-bill = 1.0 and 2026 guidance of ~4% sales growth to $43.8B imply demand flat versus 2025. Winners are lower-valuation primes and niche suppliers with better FCF conversion; losers are richly valued systems integrators (NOC at 30.5x P/FCF) whose multiple requires >mid-single-digit organic growth to justify price. Cross-asset: weaker NOC will lift equity vols in defense names, may slightly widen credit spreads for BBB/BB aerospace issuers, and push risk-off flows into IG Treasuries; commodities and FX impact minimal. Risk assessment: Tail risks include large program cost overruns, major DoD reprioritization or export controls that reduce international sales, and a one-off FCF hit from working-capital swings — low probability but >20% P/L hit if realized. Time horizons: immediate (days) — muted; short-term (6–12 weeks) — guidance digestion and FY27 appropriations; long-term (6–24 months) — dependent on book-to-bill >1.05 to drive organic growth. Hidden dependency: GAAP vs adjusted EPS divergence and FCF below GAAP profits mean earnings quality and progress-billing timing can swing reported metrics. Trade implications: Primary actionable view is moderately bearish on NOC’s equity multiple: target a 6–12 month tactical short or put-spread to exploit downside if backlog converts slowly. Pair trades (short NOC / long GD or long TXT) capture relative re-rating if NOC’s premium compresses; use 3–6 month horizons and tighten stops on positive booking surprises. Monitor catalysts: quarterly bookings, DoD FY27 appropriations (next 60–120 days), major program awards, and management updates to FCF guide. Contrarian angles: Consensus underweights classified-program optionality and backlog quality — a one-off classified award or accelerated B-21/space contract could re-rate NOC by 10–20% quickly, so shorts must size accordingly. Reaction may be partly overdone near term given flat guidance; set threshold-based exits (e.g., guidance raise >5% or book-to-bill >1.05) to avoid squeeze. Historical parallel: post-sequestration overshoots where sector multiples recovered once budget certainty returned.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment